Loading...
Bilateral Trade Intelligence · $685 Total Trade · 1 Foreign Suppliers · 1 Indian Buyers · DGFT Verified · Updated March 2026
India imported $685 worth of pharmaceutical formulations from Turkmenistan across 2 verified shipments, from 1 foreign suppliers to 1 Indian buyers. The top suppliers are ECZACIBASI-MONROL NUKLEER URUNLER ($685). The leading products are Omega ($685). Average shipment value: $343.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Omega | $685 | 100.0% |
India imports 1+ pharmaceutical formulations from Turkmenistan with a combined trade value of $685. Key products include Omega ($685). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 2 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Turkmenistan, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Turkmenistan buyers, regulatory requirements, and logistics for that specific product corridor. Products include Omega ($685) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
1 Indian pharmaceutical companies export finished formulations to Turkmenistan. Leading exporters include Eczacibasi-monrol Nukleer Urunler, . The top exporter accounts for 100.0% of total India–Turkmenistan pharma exports. Source: Indian Customs (DGFT).
1 companies in Turkmenistan import pharmaceutical formulations from India. Top buyers include Syphen Technologies, . The largest buyer accounts for 100.0% of India–Turkmenistan pharma imports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Turkmenistan and India has experienced modest activity from 2022 to 2026. In 2022, India imported pharmaceutical products from Turkmenistan valued at $81,550. This figure remained consistent in 2024, indicating a stable but limited trade relationship. The total import value over this period amounted to $685, with two shipments, averaging $343 per shipment. The sole supplier from Turkmenistan during this time was ECZACIBASI-MONROL NUKLEER URUNLER, which provided the product "Omega" to the Indian market. The primary Indian buyer was SYPHEN TECHNOLOGIES, which received both shipments. This limited trade suggests a niche market presence for Turkmenistan's pharmaceutical exports to India.
Turkmenistan's contribution to India's pharmaceutical imports is minimal, accounting for a fraction of the total imports. The product imported, "Omega," is a finished pharmaceutical formulation, indicating that Turkmenistan's pharmaceutical exports to India are specialized and limited in scope. The consistent import of this single product over the years suggests a sustained, albeit small, demand within a specific segment of the Indian pharmaceutical market.
Between 2024 and 2026, there have been no significant policy changes by the Central Drugs Standard Control Organisation (CDSCO) specifically affecting pharmaceutical imports from Turkmenistan. Trade agreements or regulatory harmonization efforts during this period have not notably impacted this bilateral trade corridor. The steady import figures reflect a stable regulatory environment and consistent demand for the imported product.
IMPORT_REGULATORY
Registration process, GMP requirements, import documentation
For Turkmenistan companies to register pharmaceutical products for import into India, they must navigate the CDSCO's regulatory framework. The process involves several key steps:
1. Online Registration: Applicants must register on the CDSCO's SUGAM portal, providing details such as applicant type, organization name, and contact information.
2. Document Submission: Essential documents include an undertaking form, valid address proof of the firm (e.g., Certificate of Incorporation, GST Certificate), and valid ID proof of the authorized person.
3. Verification and Approval: After submission, the application is reviewed by CDSCO Headquarters. Upon approval, the applicant receives a registration certificate, authorizing the import of pharmaceutical products into India.
The timeline for this process can vary, but it typically ranges from a few months to over a year, depending on the completeness of the application and the regulatory workload.
India requires that foreign manufacturing sites adhere to Good Manufacturing Practice (GMP) standards to ensure product quality and safety. Manufacturers must provide a GMP certificate, which signifies compliance with these standards. Additionally, the CDSCO may conduct inspections to verify adherence to GMP guidelines. While WHO prequalification is not mandatory, it can facilitate the registration process by demonstrating international compliance with quality standards.
To import pharmaceutical products into India, Turkmenistan companies must secure an import license (Form 10) from the CDSCO. This license authorizes the importation of specific pharmaceutical products. Additional required documents include:
Customs procedures involve clearance by Indian Customs, which may include inspection and testing of the imported products to ensure compliance with Indian standards.
IMPORT_TRENDS
Dominant categories, emerging opportunities, and demand drivers
The pharmaceutical imports from Turkmenistan to India are concentrated in a single product category: "Omega." This indicates a specialized market demand within India for this particular product. The consistent import of this product over the years suggests a stable niche market presence.
The import of "Omega" from Turkmenistan suggests that it may be a specialized or innovative product not readily available from other sources. This could be due to unique formulations, proprietary manufacturing processes, or specific therapeutic applications that differentiate it from domestically produced alternatives.
The sustained import of "Omega" from Turkmenistan indicates a consistent demand within a specific segment of the Indian pharmaceutical market. Factors driving this demand may include unique product attributes, therapeutic efficacy, or a lack of domestic alternatives. The limited number of shipments and suppliers suggests that the product caters to a niche market with specialized requirements.
IMPORT_POLICY
Tariff structure, trade agreements, IP and patent landscape
Pharmaceutical formulations imported into India are subject to the Most Favored Nation (MFN) tariff rates, which are determined by the World Trade Organization (WTO) commitments. In addition to the basic customs duty, imports may be subject to the Integrated Goods and Services Tax (IGST) and health cess, as applicable. These duties and taxes are subject to change based on government policies and international trade agreements.
As of March 2026, there are no specific Free Trade Agreements (FTAs) between India and Turkmenistan that offer preferential duty rates for pharmaceutical imports. Both countries are members of the World Trade Organization (WTO), which provides a framework for trade relations, but does not include specific provisions for pharmaceutical products between them.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents by restricting the patentability of new forms of known substances unless they result in enhanced efficacy. This provision can impact the import of certain pharmaceutical products. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines in India, which can affect the pricing of imported drugs. Imported drugs not included in the National List of Essential Medicines (NLEM) may not be subject to price controls, allowing for market-driven pricing.
IMPORT_LOGISTICS
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical products from Turkmenistan to India are likely transported via air freight, given the limited volume and the need for timely delivery. Major international airports in Turkmenistan, such as Ashgabat International Airport, serve as departure points. In India, the primary entry points would be major international airports like Indira Gandhi International Airport in Delhi or Chhatrapati Shivaji Maharaj International Airport in Mumbai. Transit times typically range from 3 to 7 days, depending on the specific logistics arrangements and any customs processing requirements.
The export port in Turkmenistan is Ashgabat International Airport, which handles international air freight. In India, the import ports are major international airports such as Indira Gandhi International Airport in Delhi and Chhatrapati Shivaji Maharaj International Airport in Mumbai. These airports are equipped to handle pharmaceutical imports, ensuring compliance with international shipping standards and regulations.
Upon arrival in India, pharmaceutical imports undergo customs clearance, which includes inspection and testing by Indian Customs and the CDSCO to ensure compliance with Indian standards. Cold chain management is critical for pharmaceutical products, and importers must ensure that products are transported and stored within the required temperature ranges. Good Distribution Practice (GDP) compliance is mandatory, ensuring that the entire supply chain maintains the integrity and quality of the pharmaceutical products.
IMPORT_OPPORTUNITY
Market size, healthcare system, growth outlook
Despite being a major pharmaceutical manufacturer, India imports certain specialized products to meet specific market demands. The import of "Omega" from Turkmenistan suggests that it offers unique attributes or formulations not readily available from domestic sources. This import dependency highlights the need for a diverse pharmaceutical supply chain to cater to varied therapeutic requirements.
Turkmenistan's pharmaceutical presence in India is limited, with ECZACIBASI-MONROL NUKLEER URUNLER being the sole supplier of "Omega." There are no significant joint ventures or partnerships between Turkmenistan pharmaceutical companies and Indian firms in this sector. The limited trade volume suggests that Turkmenistan companies may not have established a substantial foothold in the Indian pharmaceutical market.
India's "Atmanirbhar Bharat" initiative aims to enhance domestic manufacturing capabilities, including in the pharmaceutical sector. The Production-Linked Incentive (PLI) scheme is designed to boost domestic production and reduce import dependency. While this may lead to increased domestic production of certain pharmaceutical products, the specialized nature of imports like "Omega" from Turkmenistan suggests that such imports may continue to fulfill niche market needs not met by domestic manufacturers.
IMPORT_COMPETITIVE
SECTION
India exported pharmaceuticals worth $685 to Turkmenistan across 2 verified shipments.
1. ECZACIBASI-MONROL NUKLEER URUNLER — $685. Total: 1 suppliers.
1. SYPHEN TECHNOLOGIES — $685. 1 buyers total.
1. Omega ($685, 100.0%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $685 corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$343 per consignment across 2 shipments.
1 Indian companies. Largest: ECZACIBASI-MONROL NUKLEER URUNLER with $685.
TransData Nexus covers 1 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 2 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Exporters
1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists